O2-17-06 safetyand tolerability of crenezumab in mild-to-moderate ad patients treatedwith escalating doses for up to 25 months

semanticscholar（2017）

引用 0|浏览4

暂无评分

摘要

O2-17-06 SAFETYAND TOLERABILITY OF CRENEZUMAB IN MILD-TO-MODERATE AD PATIENTS TREATEDWITH ESCALATING DOSES FOR UP TO 25 MONTHS Veronica Asnaghi, Helen Lin, Nan Hu, Jillian Smith, William Cho, Susanne Ostrowitzki, F. Hoffmann-La Roche AG, Basel, Switzerland; Genentech, Inc., South San Francisco, CA, USA; F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom; Genentech, Inc, South San Francisco, CA, USA. Contact e-mail: lin.helen@gene.com

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要